Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysis

References

• Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245
   Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20
   PubMed Web of Science ®Google Scholar
• Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124:1046-58
   PubMed Web of Science ®Google Scholar
• Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62:76-87
   PubMed Web of Science ®Google Scholar
• Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114-17
   PubMed Web of Science ®Google Scholar
• Márquez Contreras E, Vegazo García O, Martel Claros N, et al. Efficacy of telephone and mail intervention in patient compliance with antihypertensive drugs in hypertension. ETECUM-HTA study. Blood Press 2005;14:151-8
   PubMed Web of Science ®Google Scholar
• Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2010;(3):CD005182
   Google Scholar
• Muszbek N, Brixner D, Benedict A, et al. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract 2008;62:338-51
   PubMed Web of Science ®Google Scholar
• Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120:1598-605
   PubMed Web of Science ®Google Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
   PubMed Web of Science ®Google Scholar
• Dragomir A, Côté R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010;48:418-25
   PubMed Web of Science ®Google Scholar
• Lynch WD, Markosyan K, Melkonian AK, et al. Effect of antihypertensive medication adherence among employees with hypertension. Am J Manag Care 2009;15:871-80
   PubMed Web of Science ®Google Scholar
• Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care 2010;16:568-76
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013;34:2940-8
   PubMed Web of Science ®Google Scholar
• Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation 2011;123:1611-21
   PubMed Web of Science ®Google Scholar
• Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012;125:882-7.e1
   PubMed Web of Science ®Google Scholar
• Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich) 2011;13:898-909
   PubMed Web of Science ®Google Scholar
• Breekveldt-Postma NS, Penning-van Beest FJA, Siiskonen SJ, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008;24:121-7
   PubMed Web of Science ®Google Scholar
• Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19:1190-6
   PubMed Web of Science ®Google Scholar
• Yang W, Kahler KH, Fellers T, et al. Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy. J Med Econ 2011;14:267-78
   PubMedGoogle Scholar
• Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a review. Cardiovasc Diabetol 2009;8:18
   PubMed Web of Science ®Google Scholar
• Chang J, Yang W, Kahler KH, et al. Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension. Am J Cardiovasc Drugs 2011;11:21-32
   PubMed Web of Science ®Google Scholar
• Mazzaglia G, Mantovani LG, Sturkenboom MCJM, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005;23:2093-100
   PubMed Web of Science ®Google Scholar
• Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2012;11:CD002003
   PubMedGoogle Scholar
• Wiysonge CS, Opie LH. β-Blockers as initial therapy for hypertension. JAMA 2013;310:1851-2
   PubMed Web of Science ®Google Scholar
• Cheng JWM. Nebivolol: a third-generation beta-blocker for hypertension. Clin Ther 2009;31:447-62
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Samuelson TM, Ramakrishnan K, et al. Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis. Curr Med Res Opin 2012;28:591-9
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007;20:72-80
   PubMed Web of Science ®Google Scholar
• Höer A, Gothe H, Khan ZM, et al. Persistence and adherence with antihypertensive drug therapy in a German sickness fund population. J Hum Hypertens 2007;21:744-6
   PubMed Web of Science ®Google Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes. How BLS Measures Price Change for Medical Care Services in the Consumer Price Index. Washington, DC, 2010. Available at: http://www.bls.gov/cpi/cpifact4.htm [Last accessed 27 November 2013]
   Google Scholar
• US Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes. Consumer Price Index (CPI). Washington, DC, 2014. Available at: http://www.bls.gov/cpi/ [Last accessed 28 April 2014]
   Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Kettani F-Z, Dragomir A, Côté R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009;40:213-20
   PubMed Web of Science ®Google Scholar
• Elliott WJ. Compliance – and improving it – in hypertension. Manag Care 2003;12:56-61
   PubMedGoogle Scholar
• Koçkaya G, Wertheimer A. Can we reduce the cost of illness with more compliant patients? An estimation of the effect of 100% compliance with hypertension treatment. J Pharm Pract 2011;24:345-50
   Google Scholar
• Di Lenarda A, Remme WJ, Charlesworth A, et al. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Eur J Heart Fail 2005;7:640-9
   PubMed Web of Science ®Google Scholar
• Abraham WT, Iyengar S. Practical considerations for switching beta-blockers in heart failure patients. Rev Cardiovasc Med 2004;5(Suppl 1):S36-44
   Google Scholar
• Manrique C, Giles TD, Ferdinand KC, Sowers JR. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens (Greenwich) 2009;11:369-75
   PubMed Web of Science ®Google Scholar
• Weiss RJ, Saunders E, Greathouse M. Efficacy and tolerability of nebivolol in stage I–II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin Ther 2011;33:1150-61
   PubMed Web of Science ®Google Scholar
• Kumar D, Loc B. Nebivolol a novel somewhat different beta adrenergic receptor blocker. J Drug Deliv Ther 2013;3:185-91
   Google Scholar
• Ladova K, Vlcek J, Vytrisalova M, Maly J. Healthy adherer effect – the pitfall in the interpretation of the effect of medication adherence on health outcomes. J Eval Clin Pract 2014;20:111-16
   PubMed Web of Science ®Google Scholar
• Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992;304:405-12
   PubMedGoogle Scholar
• Sawicki PT, McGauran N. Have ALLHAT, ANBP2, ASCOT-BPLA, and so forth improved our knowledge about better hypertension care? Hypertension 2006;48:1-7
   PubMed Web of Science ®Google Scholar